Sustained release of PKR inhibitor C16 from mesoporous silica nanoparticles significantly enhances mRNA translation and anti-tumor vaccination

Wei Zhang,Yi Liu,Jas Min Chin,Kyle K L Phua,Kyle K.L. Phua
DOI: https://doi.org/10.1016/j.ejpb.2021.03.011
IF: 5.589
2021-06-01
European Journal of Pharmaceutics and Biopharmaceutics
Abstract:<p>In this study, we developed a mesoporous silica nanoparticles - mRNA (MSN-mRNA) subcutaneous delivery system composed of naked mRNA and a subcutaneous depot of imidazolo-oxindole RNA-activated protein kinase (PKR) inhibitor C16. We show that C16 treatment during mRNA transfection is a potent immune evasion approach that non-linearly enhances translation of unmodified mRNA in both mouse fibroblasts and dendritic cells <em>in vitro</em> exceeding that of nucleoside-modified mRNA. Notably, C16 further enhances translation of nucleoside-modified mRNA and HPLC purified mRNA. However, translation enhancement is dependent on and potentiated by C16's continuous presence. C16 mediated translation enhancement is extended <em>in vivo</em> by employing MSN as an interface to sustain-release C16. Subcutaneously administered MSN-mRNA significantly enhanced <em>in vivo</em> translation and expression kinetics of naked mRNA in unmodified, nucleoside-modified, and HPLC purified formats. We applied a MSN-mRNA vaccine formulation composed of naked mRNA encoding ovalbumin and granulocyte macrophage colony stimulating factor, and on a xenograft E.G7-OVA prophylactic tumor model, resulting in very potent tumor inhibition. The MSN-mRNA delivery system bears great translational potential in mRNA therapeutics.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?